

UC Davis

UC Davis Previously Published Works

Title

Biomechanical relationships between the corneal endothelium and Descemet's membrane

Permalink

<https://escholarship.org/uc/item/3tw248kq>

Journal

Experimental Eye Research, 152

ISSN

0014-4835

Authors

Ali, Maryam

Raghunathan, VijayKrishna

Li, Jennifer Y

et al.

Publication Date

2016-11-01

DOI

10.1016/j.exer.2016.09.004

Peer reviewed



Published in final edited form as:

Exp Eye Res. 2016 November ; 152: 57–70. doi:10.1016/j.exer.2016.09.004.

Biomechanical relationships between the corneal endothelium and Descemet's membrane

Maryam Ali^{a,1}, VijayKrishna Raghunathan^{a,b,1}, Jennifer Y. Li^{c,1}, Christopher J. Murphy^{a,1,c}, and Sara M. Thomasy^{a,1}

^aDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA 95616

^bThe Ocular Surface Institute, College of Optometry, University of Houston, Houston, TX, USA 77204

^cDepartment of Ophthalmology & Vision Science, School of Medicine, UC Davis Medical Center, Sacramento, CA, USA 95817

Abstract

The posterior face of the cornea consists of the corneal endothelium, a monolayer of cuboidal cells that secrete and attach to Descemet's membrane, an exaggerated basement membrane. Dysfunction of the endothelium compromises the barrier and pump functions of this layer that maintain corneal deturgescence. A large number of corneal endothelial dystrophies feature irregularities in Descemet's membrane, suggesting that cells create and respond to the biophysical signals offered by their underlying matrix. This review provides an overview of the bidirectional relationship between Descemet's membrane and the corneal endothelium. Several experimental methods have characterized a richly topographic and compliant biophysical microenvironment presented by the posterior surface of Descemet's membrane, as well as the ultrastructure and composition of the membrane as it builds during a lifetime. We highlight the signaling pathways involved in the mechanotransduction of biophysical cues that influence cell behavior. We present the specific example of Fuchs' Corneal Endothelial Dystrophy as a condition in which a dysregulated Descemet's membrane may influence the progression of disease. Finally, we discuss some disease models and regenerative strategies that may facilitate improved treatments for corneal dystrophies.

Keywords

Endothelium; Descemet's Membrane; Mechanotransduction; Extracellular Matrix; Topography; Modulus; Fuchs' Corneal Endothelial Dystrophy

Correspondence to: Sara M. Thomasy.

¹Current Address

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The endothelium is the most posterior layer of the cornea and plays a critical role in maintaining corneal transparency, regulating deturgescence by providing both barrier and transport functions¹. A monolayer of corneal endothelial cells (CEnCs) maintains a barrier through tight junctions and adherens junctions¹⁻⁴. Osmotic pressure drives water from the anterior segment into the corneal tissues, and the endothelial layer maintains deturgescence through active fluid transport, energetically maintained by Na⁺/K⁺-ATPases⁵⁻⁷. Corneal endothelial cells also produce a specialized basement membrane that forms Descemet's membrane (DM)⁸. Anterior to DM is the stroma, which constitutes the bulk of the cornea⁹. Bowman's layer¹⁰, a specialized acellular extracellular matrix (ECM), separates the stroma from the anterior corneal epithelium in humans, but is absent in all domestic animals¹¹. A stratified squamous nonkeratinized epithelium makes up the anterior face of the cornea, with basal columnar cells are anchored to the underlying anterior basement membrane¹¹.

It is well-documented that biophysical cues, such as substratum topography and stiffness, intrinsic attributes of all extracellular matrices, profoundly modulate a host of fundamental cell behaviors¹²⁻²⁰. Corneal cells interact with a rich variety of *in vivo* biophysical stimuli: the stroma and basement membranes present them with a range of stiffnesses and complex topographies²¹. Our laboratory and others have documented that the biophysical attributes of matrices represent ubiquitous and potent cellular stimuli that modulate morphology²²⁻²⁶, adhesion²⁷, motility^{28,29}, proliferation³⁰, gene expression and regulation³¹, and cell differentiation^{18,20,32} in a wide array of cell types. These cues also impact how cells respond to soluble signaling molecules and therapeutic agents^{17,18,20}. Insights gleaned from research on biophysical stimuli in the cornea inform potential therapies for conditions including corneal wounds³³⁻³⁵, as well as to tissue-engineered corneal constructs for transplantation³⁶. In particular, topographical and mechanical stimuli have been introduced to CEnCs to increase proliferation^{26,30}, maintain phenotype³⁷, and produce cell sheets for transplantation³⁸⁻⁴⁰. Given the evidence supporting the role of mechanical signals in the function of CEnCs, it is surprising that the roles of these signals in homeostasis and pathogenesis have not been explored more thoroughly.

In this review, we present evidence that biophysical interactions must be considered when developing a complete model of the corneal endothelium in health and disease. We begin by describing experimental methods used to explore the biophysical microenvironment of corneal cells, particularly the stiffnesses of the tissues with which these cells interact. Next, we describe the ultrastructure of DM and the variations in the ECM at different stages of an organism's lifespan. We then highlight the signaling pathways that are likely to be involved in transducing mechanical signals from the ECM to the nucleus, thereby influencing cell behavior. To illustrate the reciprocal relationship between ECM and CEnCs, we describe a proposed interaction between DM and endothelial cells, engaging biophysical stimuli in Fuchs' Corneal Endothelial Dystrophy (FCED), a corneal endothelial disease marked by characteristic abnormalities of DM. We then highlight the existing literature on *in vitro* studies of ECM biomolecules produced by CEnCs. We conclude by discussing corneal endothelial regeneration, an active area of research in which a deeper understanding of mechanical cues could have a beneficial impact.

1. Methods for characterizing the biophysical properties of corneal tissues

To investigate biophysical cues and their impact, it is necessary to characterize the mechanical microenvironment that cells experience *in vivo*, and to represent these cues *in vitro*. Tissues are mechanically quantified by measuring the elastic or Young's modulus⁴¹, a property that defines the sample's stiffness or its ability to resist deformation under an applied stress⁴¹. The elastic moduli of many biological tissues including the cornea have been reported and, interestingly, the reported values for a single tissue type can span several orders of magnitude, largely depending on the method of sample preparation and/or measurement⁴² (Table 2). Tensile measurements tend to be of higher magnitude than indentation-based measurements, such as those acquired through atomic force microscopy (AFM) or mechanical interferometry imaging, as the former measures bulk deformations in the tissue (with contributions from the ECM, cells, fibrillar and network-like proteins, and constrained water⁴²) whereas the latter methods measure localized deformations on small length scales^{42,43}.

In thin, heterogeneous tissue samples such as the endothelium or DM, AFM is ideal for measuring the micron-scale deformations that cells and their local ECM environments experience^{42,44}. Our lab has extensively used AFM to characterize the stiffness of the distinct layers of the human and rabbit cornea⁴⁵⁻⁴⁷ (detailed in Table 1), as well as the normal human trabecular meshwork (4.0 ± 2.2 kPa⁴⁸). The properties of the ECM can vary considerably between species^{47,49,50}, and each layer in the rabbit eye is consistently softer than the corresponding structure in the human eye⁴⁷. For further information, we direct the reader to these reviews on the nuances of stiffness measurements in ocular tissues^{42,44} and comprehensive summaries of biomechanical measurements of ocular tissue⁵¹⁻⁵⁵.

Topographical characterization of human²¹ and canine⁵⁶ DMs using scanning electron microscopy (SEM), transmission electron microscopy (TEM), and AFM has documented DM to possess a rich felt-like surface of intertwining fibers, interspersed with elevations and pores. These features, shown in Figure 1^{56,57}, have sizes on the order of tens of nanometers and fractal dimension of ~ 2.2 ²¹. In comparison to the anterior corneal epithelial basement membrane, DM has smaller and more tightly organized features^{21,56,58,59}. The more compact organization of DM is reflected in its increased stiffness relative to the anterior corneal epithelial basement membrane^{45,47}. Cellular basement membrane assembly is influenced by cell-matrix interactions⁶⁰ and the biophysical attributes of ECM represent important inputs.

2. The development and ultrastructure of Descemet's Membrane

Like all basement membranes⁶¹, DM is a compact sheet of ECM biomolecules, including proteins and glycosaminoglycans. The composition and ultrastructure of the deposited components vary by developmental stage and pathological state⁶², forming distinct layers as they accumulate over a lifetime⁶³. Since the mechanical properties of ECM are related to its quantity, its constituent biomolecules, and its degree of crosslinking (through enzymes such as lysyl oxidase and transglutaminases)⁶⁴, we hypothesize that these variations would be reflected in differences in the biophysical cues experienced by endothelial cells on DM, as such influences have been observed in other cell types⁶⁵. Since there is no significant

remodeling of DM after deposition, the transverse view serves as an interpretable historical record of development and pathology^{63,66}.

The thickness of DM ranges from ~3 μm at birth to >10 μm in old age⁶³. The anterior region is deposited prenatally, from ~12 weeks after conception, to birth⁶³. By 16 weeks after conception, a striated pattern appears in transverse sections⁶³ and is known as the anterior banded layer (ABL), composed primarily of collagen IV and collagen VIII^{67,68}.

Ultrastructurally, in the ABL collagen VIII forms several layers of stacked hexagonal lattices^{62,68}, shown in Figure 2^{69–71}. The lattice pattern arises from the molecular structure of collagen VIII as two types of short polypeptide chains, $\alpha 1$ and $\alpha 2$, assemble into homotrimers, then into a tetrahedral intermediate structure, and finally into hexagonal lattices⁷² which form characteristic bands (with 100 nm spacing) when stacked^{62,73}. In normal human corneas, the two types of collagen VIII polypeptide chains are co-localized as bands within the ABL⁷⁴. This characteristic banded pattern of the ABL is entirely absent in knock-out mutant mice that lack genes for both the $\alpha 1$ and $\alpha 2$ polypeptide chains⁷⁵. These mice have thinner DMs and a lower endothelial cell count suggesting the ABL to be critical to endothelial cell proliferation during development⁷⁵.

Near birth, endothelial cell secretion of collagen VIII diminishes as the cells transition from a proliferative to non-proliferative state, but collagen IV secretion continues^{8,75,76}. The ECM deposited thereafter lacks the banded pattern and is known as the posterior non-banded layer (PNBL)⁶². The PNBL can be interspersed with small inclusions of fibrillar or banded ECM thought to arise from endothelial cells that transiently lose their postnatal differentiated state⁶³. Such anomalous deposits are often found within guttae and Hassel-Henle warts that form in aging corneas⁶³, suggesting that these abnormal structures form when endothelial cells undergo changes in ECM expression patterns over a lifetime. At this time, to the authors' knowledge, possible differences in the biophysical attributes of the PBL and PNBL remain unexplored. We feel it is likely that both compliance and/or topographic features would differ between these distinct regions of DM and that if such differences are present that they would influence the CEnC phenotype.

3. Biophysical signaling in the corneal endothelium

Since DM is the major source of biophysical stimuli for CEnCs, and since the cells themselves produce the ECM comprising DM, there is a bidirectional relationship between endothelial cells and the ECM they deposit^{66,77} (Figure 3). Such a relationship, known as “dynamic reciprocity”^{78–80}, has been observed in many physiological systems, including the corneal stroma³⁴. A detailed understanding of the signaling pathways that underlie these bidirectional relationships may reveal new targets for therapeutic intervention by interrupting the positive feedback loop of dysfunctional ECM – produced under pathological conditions – inducing further pathological cell behavior. The primary pathway impacted by the biophysical attributes of DM is the mechanotransduction pathway, which intersects downstream with the Hippo⁸¹, transforming growth factor β (TGF- β)⁸², Wntless/int (Wnt)^{83,84}, and other signaling pathways⁸⁵ that control gene expression. The intersection of critical signaling pathways is presented in Figure 4⁸⁶.

Mechanotransduction

Mechanotransduction is the process by which cells sense extracellular mechanical cues, including ECM stiffness, topography, and spatial constraints, and convert them into intracellular biochemical signals leading to cellular responses^{14,15}. Transmembrane mechanoreceptors such as integrins and syndecans bind to ECM molecules and detect stresses in the extracellular environment⁸⁷. On the cytoplasmic side, they are linked to the actin cytoskeleton which is critical in generating and transmitting tension throughout the cell, controlling cell morphology and activating downstream signaling pathways⁸⁸. The cell can probe the stiffness of its surroundings by contracting its actin cytoskeleton – a compliant substrate offers less resistance to deformation and induces less stress in the contractile machinery than a stiff one⁸⁸. Mechanical stresses transmitted through mechanoreceptors to the cytoskeleton can alter the assembly dynamics of actin filaments, inducing conformational changes in actin-binding proteins that play regulatory roles further downstream⁸⁹. The cytoskeleton also links to structures in the nucleus, coupling integrin activation directly to nuclear conformational changes and gene transcription activity⁹⁰. It thus plays a central role in enabling extracellular biophysical cues to regulate a variety of cell behaviors, including survival, proliferation, differentiation, migration, adhesion, and polarity^{88,91–93}. Integrins additionally regulate the actin cytoskeleton⁹⁴ by activating the Rho/ROCK pathway through Src-family kinases and Rho-family GTPases⁹⁵ and influence migration, proliferation, and apoptosis⁹⁶. Rho-associated protein kinase (ROCK) has been linked to proliferation^{97–101}, wound healing processes^{33,98,102–104} and the barrier function^{1,105–107} in CEnCs¹⁰⁰.

YAP/TAZ and Hippo

The Hippo pathway, critical for management of organ size during development, has been recently shown to intersect with the mechanotransduction pathway. Two transcriptional regulators and key players in the Hippo pathway, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), were identified by Dupont and colleagues as a necessary relay for conveying mechanotransduction signals to the nucleus for gene regulation^{81,108}. In cells adherent to soft substrates or confined to a small area, YAP/TAZ accumulate in the cytoplasm and eventually degrade, whereas when cells are spread or attached to stiff surfaces, YAP/TAZ relocate to the nucleus and induce gene expression^{81,109}. The mechanisms behind these localization patterns are unclear, although the regulation of the actin cytoskeleton by the mechanotransduction pathway appears to play key roles^{81,108}. For instance, G-protein coupled receptors acting through the actin cytoskeleton inhibit YAP localization in the nucleus by acting on LATS 1/2¹¹⁰. The specific roles of YAP/TAZ in the corneal endothelium are currently under investigation: YAP expression in the nucleus and cytoplasm increases in CEnCs at the periphery of the endothelium, coinciding with higher proliferative potential¹¹¹. Additionally, cultured CEnCs have been induced to proliferate by increasing YAP expression¹¹². Because YAP and TAZ are targets and effectors of numerous cell-signaling pathways, including Hippo, TGF- β , Akt, and both canonical and non-canonical Wnt pathways^{86,113,114}, they can orchestrate the influence of mechanical cues on a wide range of cell behaviors, including epithelial-mesenchymal transition¹¹⁵.

TGF- β

Members of the TGF- β family are cytokines that are generally inactive in the ECM until released upon injury or mechanical stress, and then bind to membrane receptors¹¹⁶. This initiates downstream signaling, activating several types of Smad proteins that form a complex, translocate to the nucleus, and promote transcription.¹¹⁶ In CEnCs and other cell types, they induce the synthesis, remodeling, and degradation of ECM proteins¹¹⁷, and trigger the transdifferentiation activity known as epithelial-mesenchymal transition (EMT)^{118–120}, which is a feature of FECD^{121–124}. Changes in matrix protein expression are likely to alter the biophysical properties of the secreted ECM, invoking a mechanotransduction response within the cell. Additionally, the Smad protein complex interacts with YAP/TAZ in some cells to evoke an enhanced fibrotic or metastatic response^{116,125}. Through these mechanisms, the TGF- β pathway may impact the dynamic reciprocity between CEnCs and the ECM.

AKT

The Akt pathway promotes survival and growth in response to extracellular signals, including cytokines, hormones, and ECM interactions. It is initiated when the cell surface receptor phosphatidylinositol 3-kinase (PI3K) is activated. Akt, a serine/threonine kinase, is then activated and initiates downstream processes¹²⁶. In CEnCs, fibroblast growth factor 2 (FGF-2) initiates the Akt pathway and promotes proliferation¹²⁷. Furthermore, Akt-induced proliferation in CEnCs is inhibited by TGF- β 2 via the latter's transcription products¹²⁷. The Akt pathway also intersects with the downstream relays of the mechanotransduction pathway: Akt interacts with YAP/TAZ and localizes them in the cytoplasm while limiting their degradation¹²⁸. Through these interactions, the Akt pathway has multiple impacts on dynamic reciprocity.

Wnt

The Wnt pathway plays key roles in development, homeostasis, disease, and mechanotransduction. In the canonical pathway, Wnt ligands bind to membrane receptors, initiating a downstream signaling cascade that stabilizes intracellular β -catenin, saving it from degradation and allowing it to regulate transcription in the nucleus¹¹⁶. If sufficient Wnt antagonists are present, the pathway is inhibited and cytoplasmic β -catenin is marked for degradation, limiting its transcriptional activity¹¹⁶. However, β -catenin can be rescued from degradation by association with YAP/TAZ. The Wnt pathway is thereby influenced by downstream relays of mechanotransduction. A few more interactions are worth noting: In the corneal endothelium, matrix metalloproteinase inhibitors can reverse EMT through inhibiting the Wnt pathway, thereby linking pathological cell behavior to ECM remodelling¹²⁹. A non-canonical (β -catenin independent) Wnt pathway regulates the cytoskeleton via Rho GTPases¹³⁰. Rho GTPases activated through PI3K are linked to increased EMT in CEnCs¹³¹. This EMT increase occurs when CEnCs are induced to proliferation through disruption of their junctions and the addition of FGF-2¹³¹. However, Wnt activation can be bypassed by silencing nuclear p150 catenin to activate the Rho pathway¹³². All these interactions provide points at which the Wnt pathway can have an influence on the dynamic reciprocity between the endothelium and DM.

The signaling pathways described above converge on two cellular responses in particular: proliferation and EMT-induced ECM expression. Changes in the ECM, in turn, influence the cell mechanically, creating a closed loop of influence in which abnormal matrix can trigger the expression of more abnormal matrix. Both cellular responses are relevant to the corneal endothelium in health and disease.

4. Dysfunction of the corneal endothelium

Primary corneal diseases are widespread and represent the third leading cause of blindness^{70,133}. Diseases of the corneal endothelium are especially burdensome. While the CEnCs of some species, such as rabbits and cows, retain some proliferative capabilities throughout life¹³⁴, human CEnCs are especially notable for their low proliferation rate, which is insufficient to replace cells lost through age, trauma, or disease¹³⁵. The remaining cells migrate and enlarge to maintain the intact monolayer¹³⁶ leading to subsequent cellular polymegethism and pleomorphism in the endothelium¹³⁷. If the endothelial cells cannot maintain an intact monolayer, their barrier as well as pump functions are disrupted leading to stromal edema and a progressive decrease in visual acuity⁷⁰. The endothelium can degenerate because of primary corneal dystrophies, or secondary to other disturbances to the eye such as glaucoma¹³⁸, uveitis¹³⁹, or intraocular surgery¹⁴⁰. The likelihood of secondary changes such as bullous keratopathy are increased if the endothelium has pre-existing signs of vulnerability, and candidates for anterior segment surgery should be screened for low endothelial cell counts^{141–143}. The health of CEnCs is closely linked to the state of DM to which they adhere. Many dystrophies are associated with the production of abnormal ECM or amyloid deposits that are likely to change the topography and modulus of the membrane^{144,145}, suggesting that biophysical interactions with cells may have an impact on a wide range of corneal diseases. Here, we provide a brief introduction of the biophysical properties associated with corneal endothelial dystrophies.

4.1 Fuchs' Corneal Endothelial Dystrophy

Fuchs' Corneal Endothelial Dystrophy (FCED) is the most common corneal endothelial dystrophy in the United States⁷⁰. Clinically, FCED manifests as a thickened and multi-layered DM, with the presence of corneal guttae, corneal edema and deterioration of vision⁷⁴.

It occurs in two forms, a late-onset variant and a rarer early-onset variant¹⁴⁶. In addition to their clinical presentation of thickened DM and gutta formation, the two forms of FCED involve Collagen VIII in distinct ways. Fuchs' dystrophy has been linked to mutations in genes with a variety of functions, begging the question of how a diverse set of genes lead to the common phenotype of abnormal ECM production. Here, we discuss the alterations of ultrastructure and composition of DM in FCED, discuss the associated genetic anomalies that may alter the ECM composition and organization, and consider how these changes may impact intrinsic biophysical attributes, cell function and survival.

Ultrastructural studies of DM in FCED patients reveal a characteristic pattern. Descemet's membrane of FCED patients' corneas is thicker than that of age-matched normal corneas, although the PNBL is thinner. In late-onset FCED, the ABL is slightly thicker than normal.

There is a gradual transition from the PNBL to a posterior collagenous layer (PCL) interspersed with banded patterns termed “widespaced collagens” similar to that of the ABL^{62,66,147}. Some corneas, particularly those with pronounced edema, also have a loose “fibrillar layer” between the banded PCL and endothelial cells¹⁴⁷. The arrangement of wide-spaced, amorphous, and fibrillar ECM is increasingly irregular and distorted toward the posterior of the cornea¹⁴⁷. The guttae that appear on the posterior DM in FCED are also composed of ECM similar to the PCL¹⁴⁷. In early-onset FCED, the ABL is notably thicker than normal⁷⁴. It is followed by a PNBL similar to that in late-onset FCED, and an internal collagenous layer (ICL) reminiscent of the PCL in late-onset FCED⁷⁴. Posterior to this is a very thick, collagen VIII-rich posterior striated layer, which does not occur in late-onset FCED⁷⁴. Guttae are smaller than in late-onset FCED and buried within other deposited ECM material¹⁴⁸.

Corneal endothelial cells have the latent ability to synthesize a larger set of ECM protein types than they normally produce, and diseases may arise when regulation of protein expression is dysfunctional¹⁴⁹. In late-onset FCED, there is increased deposition of collagen IV, laminin, fibronectin, and several other ECM components in the posterior of DM^{74,150}.

While Collagen VIII is normally found only in the ABL of DM, appearing as arrayed domains of the $\alpha 1$ and $\alpha 2$ chains⁷⁴, this arrangement of Collagen VIII is disrupted in FCED. Collagen VIII are also expressed in the PCL, indicating that its production is resumed after cessation in infancy⁶². Interestingly, Collagen VIII plays a different but central role in early-onset FCED also. This condition is associated with mutations in COL8A2. A few familial pedigrees and sporadic individuals have been identified that carry missense mutations in COL8A2 (either Q455K, Q455V, or L450W^{148,151}). In patients with the L450W mutation, intracellular and extracellular collagen VIII accumulation correlated with the severity of the disease¹⁵². Corneas of patients with early-onset FCED, as well as corneas in mouse models with COL8A2 knock-in mutations, have a thickened DM, guttae, changes in endothelial cell morphology, and cell loss, supporting the idea that mutations in Collagen VIII can produce signs of FCED independently of other mutations^{153,154}.

It is as yet unclear what mechanisms trigger changes from one type of ECM composition to another, and why the various layers in normal and pathogenic DMs appear as they do. However, we can speculate on how these ECM alterations modify the biophysical environment experienced by cells. For instance, since point mutations can affect protein folding, it is likely that mutant COL8A2 in early-onset FCED leads to the expression of collagen VIII chains that do not assemble into the same macromolecular structures as normal chains do¹⁵⁵. This could alter the biophysical properties of DM, thereby triggering expression changes within the cell.

In addition to the COL8A2 mutations in early-onset FCED, several genetic mutations have been associated with FCED, and these are comprehensively reviewed in the literature^{70,156}. The affected genes TCF4 and TCF8 express the transcription factors E2-2 and ZEB1 respectively, which are known to promote EMT^{157,158}. TCF8 also alters the expression of Collagen IV, which is abundant in DM¹⁵⁹. Changes in these key functions of ZEB1 may contribute to abnormal ECM deposition. Several mutations, in COL8A2¹⁵², SLC4A11¹⁶⁰,

and LOXHD1¹⁶¹, cause cytoplasmic accumulation of proteins. These may induce gutta formation through a mechanism involving the accumulation of proteins in the endoplasmic reticulum, and subsequent unfolded protein response, that has been proposed by Son, et al¹⁶².

In FCED, the PCL is less stiff than the PNBL of the normal DM, and this may be due to alterations in the composition, assembly patterns, and hydration content of the matrix^{163,164}. The composition of the ECM can greatly influence the modulus¹⁶⁵. The heterogeneity of the PCL ultrastructure may interrupt the packing structure of ECM biomolecules, changing the PCL density and modulus relative to the normal PNBL^{166,167}. As the DM is normally defined by the network structure of collagen IV, the presence of a fibrillar layer is also likely to change the surface attributes with which endothelial cells interact¹⁶⁸. Wide-spaced collagens also alter the topography of the DM surface, as revealed by AFM imaging¹⁶³.

As guttae are physical structures growing on DM, they exert particular biophysical cues on CECs. The guttae appear as round, flat-topped growths that are 5 to 50 μm in diameter¹⁶³ and up to 20 μm in height¹⁶⁹. The height of topographic features has been shown to impact cell behaviors though at scales significantly smaller than guttae¹⁷⁰. A preliminary report suggests that the micron-scale dimensions of guttae can impact CEnC behaviors including migratory behavior and monolayer formation *in vitro*¹⁵². In histopathological sections of FCED corneas, the cells exhibit a spread morphology over guttae with cell bodies displaced laterally to the guttae stems but with sections of cell membrane intact over gutta apices¹⁷¹. This displacement is sufficient to distort the cells and apply tensile forces to their actin cytoskeletons. Such mechanical stretch has been associated with EMT in other cell types¹⁷², and this distortion of CEnCs may induce or contribute in part to the EMT-like behavior seen in FCED. With limited space for organelles in the stretched areas and for Na^+/K^+ -ATPase on the diminished lateral membranes, the pump function of the corneal endothelium may be quite diminished¹⁷¹. However the barrier function of the endothelium is retained as cells remain adherent to one another until late in disease progression¹⁷¹.

For a complete understanding of the role of biophysical cues in pathogenesis of FCED, we need to fully characterize the biophysical cues presented by DM in FCED, understand how the signaling pathways initiated by mechanotransduction determine the downstream impact on cell health, gutta formation and ECM protein expression. While there are several animal models for FCED, including transgenic mice^{153,154} and Boston terriers¹⁷³, the biophysical attributes of DM and endothelium in these species remains uncharacterized. Given the challenges in observing the early development of FCED, *in vitro* cell models of the disease could help us fill these knowledge gaps.

4.2 Other endothelial disorders

Posterior Polymorphous Corneal Dystrophy is a rare, slowly progressive or non-progressive condition that develops during the first decade of life but is often asymptomatic.¹⁷⁴ It is characterized by a multilamellar DM with vesicle- and band-like lesions and focal nodular excrescences^{70,175}. Congenital hereditary endothelial corneal dystrophy presents as a cloudiness or opacification and edema of the cornea that is present at birth or develops in infancy⁷⁰. Disruption of collagen fibrils occurs in the stroma as well as the production of a

fibrous collagen layer posterior to DM⁷⁰. Subepithelial amyloid deposits have been reported in several cases^{156,176–179}. X-linked corneal endothelial dystrophy was recently discovered in 60 members of a single family¹⁸⁰. The corneas developed opacifications including congenital cloudiness, subepithelial band keratopathy, and endothelial pits¹⁸⁰. Examination of one cornea revealed an irregularly thickened DM, consisting of an abnormal ABL, an abnormal posterior banded zone of varying ultrastructure and thickness, and an absent PNBL¹⁸⁰. Iridocorneal endothelial syndrome (ICE) is a group of related corneal disorders in which endothelial cells migrate onto the iris and block the drainage angle, leading to iris atrophy and glaucoma¹⁸¹. In a study of 27 ICE affected corneas, the majority possessed DMs with a posterior layer of microfibrils embedded in an amorphous matrix. In several others, there were no banded collagenous layers either anterior or posterior to the non-banded layer¹⁸². The commonality in features across several corneas suggests these patterns are specific to the mechanisms of ICE¹⁸².

Although the mechanical, topographical, and biochemical properties of DM in these diseases have not been well characterized, we note a recurring incidence of abnormal ultrastructure and the appearance of lesions, excrescences and craters in DM^{70,175,180,181,183}. These features very likely offer abnormal topographical and mechanical cues to endothelial cells growing on and interacting with the membrane, which could trigger pathological processes such as EMT¹⁸⁴ or apoptosis¹⁸⁵. While it is yet unclear whether these biophysical abnormalities in DM are responsible for, or merely coincide with, endothelial cell dysfunction and premature degeneration, there are other instances in the biomedical literature of dysregulated extracellular matrix causing pathological behavior including fibrosis, atherosclerosis and tumorigenesis^{186,187}. Furthermore, our lab has demonstrated that changes to substratum compliance and topography can promote the transformation of corneal fibroblasts to myofibroblasts^{18,20}, leading us to hypothesize that the biophysical characteristics of DM impact endothelial cell morphology and function.

5. *In vitro* studies of ECM in corneal endothelial cells

To delineate the mechanisms of corneal endothelial dystrophies and identify efficacious treatments, it is critical to establish *in vitro* disease models using cell culture. A complete description of mechanism needs to capture the bidirectional interactions between cells and ECM, and characterize ECM expression changes in the presence of mutations, stress, EMT, and disease states. While some studies of CECs have measured ECM gene and protein expression changes, the resulting matrix has rarely been characterized.

The major protein component of the ECM expressed by CEnCs is collagen¹⁸⁸, predominantly collagens IV, VIII, XII, and XIII¹⁵⁰. The production of a matrix, similar to DM in appearance and collagen content, by rabbit CEnCs was first reported in 1974¹⁸⁹. Over the next two decades, studies showed that the content of the ECM produced by CEnCs could be modulated by treating the cell culture with growth factors, such as FGF-2¹⁹⁰ and TGF- β ¹¹⁷, that also play a role in EMT¹⁹¹. Cells cultured at suboptimal conditions, e.g. passaged repeatedly at subconfluence in the absence of FGF-2, eventually shift to a higher production of collagen I¹⁸⁸. One study demonstrated that ECM production by CEnCs in response to TGF- β depends on the expression levels of the EMT-inducers Snail1 and ZEB1,

which tend to be elevated in FCED-derived cells¹²¹. Immortalized cells derived from normal and FCED-affected endothelia were cultured to deposit ECM on polyester membranes, and transmission electron microscopy was used to quantify and compare the thicknesses of the deposited matrices. In the FCED-derived cells, expression of collagen I, collagen IV, and fibronectin was elevated, and the ultrastructure revealed more fibrillar ECM compared to normal phenotype cells.

A key *in vitro* strategy to understanding the role of ECM in disease and mechanotransduction is to culture cells on ECM substrates with differing biophysical attributes and investigate their responses. An early study culturing normal CEnCs for a week on FCED-derived DM did not show abnormalities in morphology or monolayer formation, although the study was limited in time and did not investigate cell function¹⁹². Interestingly, cells cultured on pseudophakic bullous keratopathy-derived membranes adopted an abnormal non-confluent stellate form, indicating that this rapid-onset condition disrupts DM and modulates cell growth more acutely¹⁹². CEnCs have also been plated on ECM-coated tissue culture dishes¹⁹³ and soft substrates³⁷ to assess which surfaces best promote the normal corneal endothelial phenotype. Synthetic substrates that are biomimetic of DM stiffness have also been developed, particularly to enhance proliferation and monolayer stability in artificial corneal grafts^{37,194}. Another approach to study cell response to ECM is to deposit a matrix from cells in a long-term culture, decellularize the matrix, and then use the matrix as a substrate for a *de novo* cell culture¹⁹⁵ but this approach has not been applied to CEnCs to the authors' knowledge.

The development of *in vitro* models that mimic both homeostatic and disease states would better enable us to recapitulate the abnormal ECM signals in corneal dystrophies, assess their impact on cell fate, and characterize the resultant expressed matrix biomolecules.

6. Impact of biophysical cues on regenerative treatments

The successful *in vitro* culture of CEnCs is a prerequisite for novel regenerative treatments. Presently, the most common treatment for corneal endothelial dystrophies is transplantation of the full-thickness cornea or DM with associated CEnCs, but a global shortage of available donors has driven the development of cell replacement therapy approaches¹⁹⁶ and synthetic corneal endothelium grafts^{196,197}. Cell replacement therapy involves the culture and expansion of CEnCs *in vitro*, and subsequent transplantation into the eye without a carrier material. Successful cultures have been established by overcoming proliferative arrest of CECs through the disruption of junctions¹⁹⁸, and treatment with small molecules (e.g. Rho-kinase inhibitors)^{104,112} and growth factors (e.g. FGF-2)^{188,199}. Furthermore, corneal endothelial precursor cells from the peripheral cornea have a higher than average proliferative capacity and corneal endothelial stem cells are located in a sequestered niche at the limbus between the endothelium and trabecular meshwork²⁰⁰. Cultures established with the endothelial stem cells have been delivered into animal models of bullous keratopathy, where they adhered to DM and enhanced corneal clarity²⁰¹.

For ease of delivery, it may be necessary to culture corneal endothelial cells on a carrier before implanting the construct as an artificial graft. Grafts have been prepared by culturing

endothelial cells on native tissue such as decellularized DMs²⁰², amniotic membranes²⁰³, and lens capsules²⁰⁴. Carriers of cultured cells have also been synthesized with biological materials such as collagen I^{205,206}, silk fibroin²⁰⁷, and chitosan²⁰⁸. ECM-based coatings are frequently applied to the carriers to enhance cell function^{193,209–211}. Blended biomaterials combine the desired properties of their components to produce surfaces that have clarity, biocompatibility, and mechanical strength^{212,213}. Another desired trait, the non-destructive detachment of intact endothelial monolayers, has been achieved through the development of thermoresponsive^{38,214,215} and biodegradable^{208,212,214,216} substrates.

These artificial grafts and carriers have not yet recapitulated the functionality of the native cornea to a clinically-relevant degree: cell density and quality do not match the native endothelium, the Na⁺/K⁺-ATPase pump function is 75–95% that of normal human donor corneas, and the corneas grafted with cellularized matrices eventually lose their transparency¹⁹⁷. Introducing optimized biophysical cues into matrix design parameters may alleviate many challenges in recapitulating corneal function in these artificial constructs by improving functional protein expression. Endothelial cell morphology is dramatically improved on substrates imitating the stiffness of normal DM in comparison to softer or stiffer substrates³⁷. Similarly, cells grown on substrates presenting biomimetic topographic cues also exhibited differential protein expression. Immortalized human CEnCs grown on nanopillars, micropillars, and microwells displayed varied levels of the ZO-1 and Na⁺/K⁺-ATPase proteins, with the highest expression on substrates that minimized the cells' surface area²⁶.

The mechanical properties of carrier materials have been improved to produce substrates that are strong enough to survive cell culture and handling, but the provision of biophysical cues has not been adequately explored and this remains an understudied area. Incorporation of these features into the design of carrier substrates may be critical to developing grafts with long-term success.

Conclusion

CEnCs, and the matrix that they secrete to produce the DM, have a bidirectional relationship. Corneal endothelial health relies on a normal and intact DM, and in turn healthy endothelial cells are necessary for the production of a normal extracellular matrix. This relationship in endothelial health and disease has been understudied and it critical that we consider the role of biophysical signals provided by the ECM. Fortunately, there are many tools available to characterize the cells' mechanical microenvironment and recapitulate it *in vitro* to provide a better model of what the corneal endothelium senses *in vivo*. The insights gleaned from investigating these interactions will expand our understanding of the pathogenesis of corneal endothelial dystrophies, and lead to improved outcomes for treatments.

Acknowledgments

The authors thank Dr. Paul Russell for his generous input during the preparation of this document and Dr. Chrisoula Skouritakis, Director of Media Lab Services of the Department of Surgical and Radiological Sciences, for her assistance in preparing figures.

Funding:

This study was funded by grants from the National Institute of Health K08 EY021142, R01 EY019970, R01 EY016134, and P30 EY12576

Abbreviations

CEnC	corneal endothelial cells
ECM	extracellular matrix
DM	Descemet's membrane
FCED	Fuchs' corneal endothelial dystrophy
AFM	atomic force microscopy
SEM	scanning electron microscopy
TEM	transmission electron microscopy
ABL	anterior banded layer
PNBL	posterior non-banded layer
TGF-β	transforming growth factor β
Wnt	Wingless/int
YAP	Yes-associated protein
TAZ	transcriptional coactivator with PDZ-binding motif
EMT	epithelial-mesenchymal transition
PI3K	Phosphoinositide 3-kinase
FGF-2	fibroblastic growth factor-2
PCL	posterior collagenous layer
ICE	Iridocorneal endothelial syndrome

References

1. Srinivas SP. Dynamic regulation of barrier integrity of the corneal endothelium. *Optom Vis Sci.* 2010; 87:E239–254. DOI: 10.1097/OPX.0b013e3181d39464 [PubMed: 20142793]
2. Ramachandran C, Srinivas SP. Formation and disassembly of adherens and tight junctions in the corneal endothelium: regulation by actomyosin contraction. *Invest Ophthalmol Vis Sci.* 2010; 51:2139–2148. DOI: 10.1167/iovs.09-4421 [PubMed: 20019371]
3. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. *Biochim Biophys Acta.* 2008; 1778:660–669. DOI: 10.1016/j.bbame.2007.07.012 [PubMed: 17854762]
4. Noske W, Fromm M, Levarlet B, Kreusel KM, Hirsch M. Tight junctions of the human corneal endothelium: morphological and electrophysiological features. *Ger J Ophthalmol.* 1994; 3:253–257. [PubMed: 7804113]

5. Bonanno JA. Molecular mechanisms underlying the corneal endothelial pump. *Exp Eye Res.* 2012; 95:2–7. DOI: 10.1016/j.exer.2011.06.004 [PubMed: 21693119]
6. Fischbarg J. On the mechanism of fluid transport across corneal endothelium and epithelia in general. *J Exp Zool A Comp Exp Biol.* 2003; 300:30–40. DOI: 10.1002/jez.a.10306 [PubMed: 14598383]
7. Hatou S, et al. The Effects of Dexamethasone on the Na,K-ATPase Activity and Pump Function of Corneal Endothelial Cells. *Current Eye Research.* 2009; 34:347–354. Pii 910773411. DOI: 10.1080/02713680902829624 [PubMed: 19401877]
8. Kabosova A, et al. Compositional differences between infant and adult human corneal basement membranes. *Invest Ophthalmol Vis Sci.* 2007; 48:4989–4999. DOI: 10.1167/iovs.07-0654 [PubMed: 17962449]
9. Reinstein DZ, Archer TJ, Gobbe M, Silverman RH, Coleman DJ. Stromal thickness in the normal cornea: three-dimensional display with artemis very high-frequency digital ultrasound. *J Refract Surg.* 2009; 25:776–786. DOI: 10.3928/1081597X-20090813-04 [PubMed: 19772263]
10. Gordon MK, Foley JW, Birk DE, Fitch JM, Linsenmayer TF. Type V collagen and Bowman's membrane. Quantitation of mRNA in corneal epithelium and stroma. *J Biol Chem.* 1994; 269:24959–24966. [PubMed: 7929179]
11. Adler FH., Hart, WM. Adler's physiology of the eye: clinical application. 9. Mosby Year Book; 1992.
12. Hay ED. Matrix-cytoskeletal interactions in the developing eye. *J Cell Biochem.* 1985; 27:143–156. DOI: 10.1002/jcb.240270208 [PubMed: 3886675]
13. Hao J, et al. Role of extracellular matrix and YAP/TAZ in cell fate determination. *Cell Signal.* 2014; 26:186–191. DOI: 10.1016/j.cellsig.2013.11.006 [PubMed: 24216612]
14. Ingber DE. Mechanobiology and diseases of mechanotransduction. *Ann Med.* 2003; 35:564–577. [PubMed: 14708967]
15. Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. *Nat Rev Mol Cell Biol.* 2009; 10:75–82. DOI: 10.1038/nrm2594 [PubMed: 19197334]
16. Janmey PA, Miller RT. Mechanisms of mechanical signaling in development and disease. *J Cell Sci.* 2011; 124:9–18. DOI: 10.1242/jcs.071001 [PubMed: 21172819]
17. Thomasy SM, Wood JA, Kass PH, Murphy CJ, Russell P. Substratum stiffness and latrunculin B regulate matrix gene and protein expression in human trabecular meshwork cells. *Invest Ophthalmol Vis Sci.* 2012; 53:952–958. DOI: 10.1167/iovs.11-8526 [PubMed: 22247475]
18. Myrna KE, et al. Substratum topography modulates corneal fibroblast to myofibroblast transformation. *Invest Ophthalmol Vis Sci.* 2012; 53:811–816. DOI: 10.1167/iovs.11-7982 [PubMed: 22232431]
19. Raghunathan VK, et al. Role of substratum stiffness in modulating genes associated with extracellular matrix and mechanotransducers YAP and TAZ. *Invest Ophthalmol Vis Sci.* 2013; 54:378–386. DOI: 10.1167/iovs.12-11007 [PubMed: 23258147]
20. Dreier B, et al. Substratum compliance modulates corneal fibroblast to myofibroblast transformation. *Invest Ophthalmol Vis Sci.* 2013; 54:5901–5907. DOI: 10.1167/iovs.12-11575 [PubMed: 23860754]
21. Abrams GA, Schaus SS, Goodman SL, Nealey PF, Murphy CJ. Nanoscale topography of the corneal epithelial basement membrane and Descemet's membrane of the human. *Cornea.* 2000; 19:57–64. [PubMed: 10632010]
22. Petroll WM, Vishwanath M, Ma L. Corneal fibroblasts respond rapidly to changes in local mechanical stress. *Invest Ophthalmol Vis Sci.* 2004; 45:3466–3474. DOI: 10.1167/iovs.04-0361 [PubMed: 15452051]
23. Karamichos D, Lakshman N, Petroll WM. Regulation of corneal fibroblast morphology and collagen reorganization by extracellular matrix mechanical properties. *Invest Ophthalmol Vis Sci.* 2007; 48:5030–5037. DOI: 10.1167/iovs.07-0443 [PubMed: 17962454]
24. McKee CT, Raghunathan VK, Nealey PF, Russell P, Murphy CJ. Topographic modulation of the orientation and shape of cell nuclei and their influence on the measured elastic modulus of

- epithelial cells. *Biophys J*. 2011; 101:2139–2146. DOI: 10.1016/j.bpj.2011.09.042 [PubMed: 22067151]
25. Raghunathan VK, et al. Nuclear and cellular alignment of primary corneal epithelial cells on topography. *J Biomed Mater Res A*. 2013; 101:1069–1079. DOI: 10.1002/jbm.a.34417 [PubMed: 22965583]
26. Koo S, Muhammad R, Peh GS, Mehta JS, Yim EK. Micro- and nanotopography with extracellular matrix coating modulate human corneal endothelial cell behavior. *Acta Biomater*. 2014; 10:1975–1984. DOI: 10.1016/j.actbio.2014.01.015 [PubMed: 24456758]
27. Karuri NW, et al. Biological length scale topography enhances cell-substratum adhesion of human corneal epithelial cells. *J Cell Sci*. 2004; 117:3153–3164. DOI: 10.1242/jcs.01146 [PubMed: 15226393]
28. Dreier B, Raghunathan VK, Russell P, Murphy CJ. Focal adhesion kinase knockdown modulates the response of human corneal epithelial cells to topographic cues. *Acta Biomater*. 2012; 8:4285–4294. DOI: 10.1016/j.actbio.2012.07.004 [PubMed: 22813850]
29. Raghunathan V, et al. Influence of extracellular matrix proteins and substratum topography on corneal epithelial cell alignment and migration. *Tissue Eng Part A*. 2013; 19:1713–1722. DOI: 10.1089/ten.TEA.2012.0584 [PubMed: 23488816]
30. Muhammad R, et al. Micro- and nano-topography to enhance proliferation and sustain functional markers of donor-derived primary human corneal endothelial cells. *Acta Biomater*. 2015; 19:138–148. DOI: 10.1016/j.actbio.2015.03.016 [PubMed: 25796353]
31. Raghunathan VK, et al. Involvement of YAP, TAZ and HSP90 in contact guidance and intercellular junction formation in corneal epithelial cells. *PLoS One*. 2014; 9:e109811. [PubMed: 25290150]
32. Petroll WM, Lakshman N. Fibroblastic Transformation of Corneal Keratocytes by Rac Inhibition is Modulated by Extracellular Matrix Structure and Stiffness. *J Funct Biomater*. 2015; 6:222–240. DOI: 10.3390/jfb6020222 [PubMed: 25874856]
33. Okumura N, et al. Effect of the Rho Kinase Inhibitor Y-27632 on Corneal Endothelial Wound Healing. *Invest Ophthalmol Vis Sci*. 2015; 56:6067–6074. DOI: 10.1167/iovs.15-17595 [PubMed: 26393474]
34. Petroll WM, Miron-Mendoza M. Mechanical interactions and crosstalk between corneal keratocytes and the extracellular matrix. *Exp Eye Res*. 2015; 133:49–57. DOI: 10.1016/j.exer.2014.09.003 [PubMed: 25819454]
35. Gao J, et al. Biomimetic stochastic topography and electric fields synergistically enhance directional migration of corneal epithelial cells in a MMP-3-dependent manner. *Acta Biomater*. 2015; 12:102–112. DOI: 10.1016/j.actbio.2014.10.007 [PubMed: 25311684]
36. Shah A, Brugnano J, Sun S, Vase A, Orwin E. The development of a tissue-engineered cornea: biomaterials and culture methods. *Pediatr Res*. 2008; 63:535–544. DOI: 10.1203/PDR.0b013e31816bdf54 [PubMed: 18427299]
37. Palchesko RN, Lathrop KL, Funderburgh JL, Feinberg AW. In vitro expansion of corneal endothelial cells on biomimetic substrates. *Sci Rep*. 2015; 5:7955. [PubMed: 25609008]
38. Teichmann J, et al. Human corneal endothelial cell sheets for transplantation: thermo-responsive cell culture carriers to meet cell-specific requirements. *Acta Biomater*. 2013; 9:5031–5039. DOI: 10.1016/j.actbio.2012.10.023 [PubMed: 23099299]
39. Niu G, et al. Heparin-modified gelatin scaffolds for human corneal endothelial cell transplantation. *Biomaterials*. 2014; 35:4005–4014. DOI: 10.1016/j.biomaterials.2014.01.033 [PubMed: 24508079]
40. Teo BK, Goh KJ, Ng ZJ, Koo S, Yim EK. Functional reconstruction of corneal endothelium using nanotopography for tissue-engineering applications. *Acta Biomater*. 2012; 8:2941–2952. DOI: 10.1016/j.actbio.2012.04.020 [PubMed: 22522131]
41. Askeland, DR., Fulay, PP., Wright, WJ. *The science and engineering of materials*. 6. Cengage Learning; 2011.
42. McKee CT, Last JA, Russell P, Murphy CJ. Indentation versus tensile measurements of Young's modulus for soft biological tissues. *Tissue Eng Part B Rev*. 2011; 17:155–164. DOI: 10.1089/ten.TEB.2010.0520 [PubMed: 21303220]

43. Yoo L, Reed J, Gimzewski JK, Demer JL. Mechanical interferometry imaging for creep modeling of the cornea. *Invest Ophthalmol Vis Sci.* 2011; 52:8420–8424. DOI: 10.1167/iovs.11-7911 [PubMed: 21969299]
44. Last JA, Russell P, Nealey PF, Murphy CJ. The applications of atomic force microscopy to vision science. *Invest Ophthalmol Vis Sci.* 2010; 51:6083–6094. DOI: 10.1167/iovs.10-5470 [PubMed: 21123767]
45. Last JA, Liliensiek SJ, Nealey PF, Murphy CJ. Determining the mechanical properties of human corneal basement membranes with atomic force microscopy. *J Struct Biol.* 2009; 167:19–24. DOI: 10.1016/j.jsb.2009.03.012 [PubMed: 19341800]
46. Last JA, Thomasy SM, Croasdale CR, Russell P, Murphy CJ. Compliance profile of the human cornea as measured by atomic force microscopy. *Micron.* 2012; 43:1293–1298. DOI: 10.1016/j.micron.2012.02.014 [PubMed: 22421334]
47. Thomasy SM, et al. Elastic modulus and collagen organization of the rabbit cornea: epithelium to endothelium. *Acta Biomater.* 2014; 10:785–791. DOI: 10.1016/j.actbio.2013.09.025 [PubMed: 24084333]
48. Last JA, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. *Invest Ophthalmol Vis Sci.* 2011; 52:2147–2152. DOI: 10.1167/iovs.10-6342 [PubMed: 21220561]
49. Worthington KS, et al. Mechanical properties of murine and porcine ocular tissues in compression. *Exp Eye Res.* 2014; 121:194–199. DOI: 10.1016/j.exer.2014.02.020 [PubMed: 24613781]
50. Danielsen CC. Tensile mechanical and creep properties of Descemet’s membrane and lens capsule. *Exp Eye Res.* 2004; 79:343–350. DOI: 10.1016/j.exer.2004.05.014 [PubMed: 15336496]
51. Hugar DL, Ivanisevic A. Materials characterization and mechanobiology of the eye. *Mater Sci Eng C Mater Biol Appl.* 2013; 33:1867–1875. DOI: 10.1016/j.msec.2013.02.009 [PubMed: 23498207]
52. Raghunathan, VK., MJT, Russell, P. *Glaucoma Research and Clinical Advances: 2016 to 2018.* Knepper, PA., Samples, JA., editors. Vol. Ch. 8. Kugler Publications; 2016. p. 121-138.
53. Lombardo M, et al. Biomechanics of the anterior human corneal tissue investigated with atomic force microscopy. *Invest Ophthalmol Vis Sci.* 2012; 53:1050–1057. DOI: 10.1167/iovs.11-8720 [PubMed: 22266511]
54. Seifert J, et al. Distribution of Young’s modulus in porcine corneas after riboflavin/UVA-induced collagen cross-linking as measured by atomic force microscopy. *PLoS One.* 2014; 9:e88186. [PubMed: 24498254]
55. Dias JM, Ziebarth NM. Anterior and posterior corneal stroma elasticity assessed using nanoindentation. *Exp Eye Res.* 2013; 115:41–46. DOI: 10.1016/j.exer.2013.06.004 [PubMed: 23800511]
56. Abrams GA, Bentley E, Nealey PF, Murphy CJ. Electron microscopy of the canine corneal basement membranes. *Cells Tissues Organs.* 2002; 170:251–257. doi:47929. [PubMed: 11919413]
57. Bentley E, et al. Morphology and immunohistochemistry of spontaneous chronic corneal epithelial defects (SCCED) in dogs. *Invest Ophthalmol Vis Sci.* 2001; 42:2262–2269. [PubMed: 11527939]
58. Torricelli AA, Singh V, Santhiago MR, Wilson SE. The corneal epithelial basement membrane: structure, function, and disease. *Invest Ophthalmol Vis Sci.* 2013; 54:6390–6400. DOI: 10.1167/iovs.13-12547 [PubMed: 24078382]
59. Abrams GA, Goodman SL, Nealey PF, Franco M, Murphy CJ. Nanoscale topography of the basement membrane underlying the corneal epithelium of the rhesus macaque. *Cell Tissue Res.* 2000; 299:39–46. [PubMed: 10654068]
60. Glentis A, Gurchenkov V, Matic Vignjevic D. Assembly, heterogeneity, and breaching of the basement membranes. *Cell Adh Migr.* 2014; 8:236–245. [PubMed: 24727304]
61. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. *Exp Biol Med (Maywood).* 2007; 232:1121–1129. DOI: 10.3181/0703-MR-72 [PubMed: 17895520]
62. Levy SG, Moss J, Sawada H, Dopping-Hepenstal PJ, McCartney AC. The composition of wide-spaced collagen in normal and diseased Descemet’s membrane. *Curr Eye Res.* 1996; 15:45–52. [PubMed: 8631203]
63. Murphy C, Alvarado J, Juster R. Prenatal and postnatal growth of the human Descemet’s membrane. *Invest Ophthalmol Vis Sci.* 1984; 25:1402–1415. [PubMed: 6511224]

64. Miller RT. Mechanical properties of basement membrane in health and disease. *Matrix Biol.* 2016
65. Chaudhuri O, et al. Extracellular matrix stiffness and composition jointly regulate the induction of malignant phenotypes in mammary epithelium. *Nat Mater.* 2014; 13:970–978. DOI: 10.1038/nmat4009 [PubMed: 24930031]
66. Waring GO 3rd. Posterior collagenous layer of the cornea. Ultrastructural classification of abnormal collagenous tissue posterior to Descemet's membrane in 30 cases. *Arch Ophthalmol.* 1982; 100:122–134. [PubMed: 7055463]
67. Ljubimov AV, et al. Human corneal basement membrane heterogeneity: topographical differences in the expression of type IV collagen and laminin isoforms. *Lab Invest.* 1995; 72:461–473. [PubMed: 7723285]
68. Sawada H, Konomi H, Hirosawa K. Characterization of the collagen in the hexagonal lattice of Descemet's membrane: its relation to type VIII collagen. *J Cell Biol.* 1990; 110:219–227. [PubMed: 2104858]
69. Fratzl, P. Collagen: structure and mechanics. Springer; 2008.
70. Klintworth GK. Corneal dystrophies. *Orphanet J Rare Dis.* 2009; 4:7. [PubMed: 19236704]
71. Sawada H. The fine structure of the bovine Descemet's membrane with special reference to biochemical nature. *Cell Tissue Res.* 1982; 226:241–255. [PubMed: 6290070]
72. Stephan S, Sherratt MJ, Hodson N, Shuttleworth CA, Kielty CM. Expression and supramolecular assembly of recombinant alpha1(viii) and alpha2(viii) collagen homotrimers. *J Biol Chem.* 2004; 279:21469–21477. DOI: 10.1074/jbc.M305805200 [PubMed: 14990571]
73. Jakus MA. Studies on the cornea. II. The fine structure of Descemet's membrane. *J Biophys Biochem Cytol.* 1956; 2:243–252. [PubMed: 13357549]
74. Gottsch JD, et al. Fuchs corneal dystrophy: aberrant collagen distribution in an L450W mutant of the COL8A2 gene. *Invest Ophthalmol Vis Sci.* 2005; 46:4504–4511. DOI: 10.1167/iov.05-0497 [PubMed: 16303941]
75. Hopfer U, et al. Targeted disruption of Col8a1 and Col8a2 genes in mice leads to anterior segment abnormalities in the eye. *FASEB J.* 2005; 19:1232–1244. DOI: 10.1096/fj.04-3019com [PubMed: 16051690]
76. Kapoor R, et al. Type VIII collagen has a restricted distribution in specialized extracellular matrices. *J Cell Biol.* 1988; 107:721–730. [PubMed: 3047147]
77. Zagorski Z, Naumann GO. Reactive production of extracellular matrix (ECM) by corneal endothelial cells. *Acta Ophthalmol (Copenh).* 1992; 70:366–370. [PubMed: 1636400]
78. Bissell MJ, Hall HG, Parry G. How does the extracellular matrix direct gene expression? *J Theor Biol.* 1982; 99:31–68. [PubMed: 6892044]
79. Bornstein, P., McPherson, J., HS. Pathobiology of the Endothelial Cell. Nossel, HL., Vogel, HJ., editors. Academic Press; 1982. p. 215-228.
80. Bissell MJ, Aggeler J. Dynamic reciprocity: how do extracellular matrix and hormones direct gene expression? *Prog Clin Biol Res.* 1987; 249:251–262. [PubMed: 3671428]
81. Dupont S, et al. Role of YAP/TAZ in mechanotransduction. *Nature.* 2011; 474:179–183. DOI: 10.1038/nature10137 [PubMed: 21654799]
82. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. *Mol Biol Cell.* 2002; 13:902–914. DOI: 10.1091/mbc.01-08-0398 [PubMed: 11907271]
83. Akiyama T, Kawasaki Y. Wnt signalling and the actin cytoskeleton. *Oncogene.* 2006; 25:7538–7544. DOI: 10.1038/sj.onc.1210063 [PubMed: 17143298]
84. Aragona M, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell.* 2013; 154:1047–1059. DOI: 10.1016/j.cell.2013.07.042 [PubMed: 23954413]
85. Jahed Z, Shams H, Mehrbod M, Mofrad MR. Mechanotransduction pathways linking the extracellular matrix to the nucleus. *Int Rev Cell Mol Biol.* 2014; 310:171–220. DOI: 10.1016/B978-0-12-800180-6.00005-0 [PubMed: 24725427]

86. Morgan JT, Murphy CJ, Russell P. What do mechanotransduction, Hippo, Wnt, and TGFbeta have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease. *Exp Eye Res.* 2013; 115:1–12. DOI: 10.1016/j.exer.2013.06.012 [PubMed: 23792172]
87. Vogel V, Sheetz M. Local force and geometry sensing regulate cell functions. *Nat Rev Mol Cell Biol.* 2006; 7:265–275. DOI: 10.1038/nrm1890 [PubMed: 16607289]
88. Schwarz US, Gardel ML. United we stand: integrating the actin cytoskeleton and cell-matrix adhesions in cellular mechanotransduction. *J Cell Sci.* 2012; 125:3051–3060. DOI: 10.1242/jcs.093716 [PubMed: 22797913]
89. Romet-Lemonne G, Jegou A. Mechanotransduction down to individual actin filaments. *Eur J Cell Biol.* 2013; 92:333–338. DOI: 10.1016/j.ejcb.2013.10.011 [PubMed: 24252518]
90. Maniotis AJ, Chen CS, Ingber DE. Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure. *Proc Natl Acad Sci U S A.* 1997; 94:849–854. [PubMed: 9023345]
91. Choquet D, Felsenfeld DP, Sheetz MP. Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. *Cell.* 1997; 88:39–48. [PubMed: 9019403]
92. Zimmermann P, David G. The syndecans, tuners of transmembrane signaling. *FASEB J.* 1999; 13(Suppl):S91–S100. [PubMed: 10352150]
93. Ross TD, et al. Integrins in mechanotransduction. *Curr Opin Cell Biol.* 2013; 25:613–618. DOI: 10.1016/j.ceb.2013.05.006 [PubMed: 23797029]
94. Hall A. Rho GTPases and the actin cytoskeleton. *Science.* 1998; 279:509–514. [PubMed: 9438836]
95. Huvneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and Rho. *J Cell Sci.* 2009; 122:1059–1069. DOI: 10.1242/jcs.039446 [PubMed: 19339545]
96. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. *Science.* 1995; 269:1270–1272. [PubMed: 7652575]
97. Okumura N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. *Invest Ophthalmol Vis Sci.* 2009; 50:3680–3687. DOI: 10.1167/iovs.08-2634 [PubMed: 19387080]
98. Okumura N, et al. The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction. *Cornea.* 2011; 30(Suppl 1):S54–59. DOI: 10.1097/ICO.0b013e3182281ee1 [PubMed: 21912232]
99. Okumura N, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. *Am J Pathol.* 2012; 181:268–277. DOI: 10.1016/j.ajpath.2012.03.033 [PubMed: 22704232]
100. Koizumi N, Okumura N, Kinoshita S. Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models. *Exp Eye Res.* 2012; 95:60–67. DOI: 10.1016/j.exer.2011.10.014 [PubMed: 22067130]
101. Okumura N, Kinoshita S, Koizumi N. Cell-based approach for treatment of corneal endothelial dysfunction. *Cornea.* 2014; 33(Suppl 11):S37–41. DOI: 10.1097/ico.0000000000000229 [PubMed: 25188790]
102. Okumura N, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. *Br J Ophthalmol.* 2011; 95:1006–1009. DOI: 10.1136/bjo.2010.194571 [PubMed: 21398412]
103. Okumura N, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. *Invest Ophthalmol Vis Sci.* 2013; 54:2493–2502. DOI: 10.1167/iovs.12-11320 [PubMed: 23462749]
104. Okumura N, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. *Invest Ophthalmol Vis Sci.* 2014; 55:318–329. DOI: 10.1167/iovs.13-12225 [PubMed: 24106120]
105. Jalimarada SS, Shivanna M, Kini V, Mehta D, Srinivas SP. Microtubule disassembly breaks down the barrier integrity of corneal endothelium. *Exp Eye Res.* 2009; 89:333–343. DOI: 10.1016/j.exer.2009.03.019 [PubMed: 19345211]
106. Srinivas SP. Cell signaling in regulation of the barrier integrity of the corneal endothelium. *Exp Eye Res.* 2012; 95:8–15. DOI: 10.1016/j.exer.2011.09.009 [PubMed: 21963716]

107. Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP. Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF-alpha. *Exp Eye Res.* 2014; 122:77–85. DOI: 10.1016/j.exer.2014.03.004 [PubMed: 24667088]
108. Halder G, Dupont S, Piccolo S. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. *Nat Rev Mol Cell Biol.* 2012; 13:591–600. DOI: 10.1038/nrm3416 [PubMed: 22895435]
109. Dupont S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. *Exp Cell Res.* 2015
110. Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell.* 2012; 150:780–791. DOI: 10.1016/j.cell.2012.06.037 [PubMed: 22863277]
111. Zhao J, Ho J, Sutu C, Afshari NA. Regulation of YAP activity in human corneal endothelial cells. *Invest Ophth Vis Sci.* 2015; 56:4911–4911.
112. Hsueh YJ, et al. Lysophosphatidic acid induces YAP-promoted proliferation of human corneal endothelial cells via PI3K and ROCK pathways. *Mol Ther Methods Clin Dev.* 2015; 2:15014. [PubMed: 26029725]
113. Park HW, et al. Alternative Wnt Signaling Activates YAP/TAZ. *Cell.* 2015; 162:780–794. DOI: 10.1016/j.cell.2015.07.013 [PubMed: 26276632]
114. Ye X, Deng Y, Lai ZC. Akt is negatively regulated by Hippo signaling for growth inhibition in *Drosophila*. *Dev Biol.* 2012; 369:115–123. DOI: 10.1016/j.ydbio.2012.06.014 [PubMed: 22732571]
115. Diepenbruck M, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. *J Cell Sci.* 2014; 127:1523–1536. DOI: 10.1242/jcs.139865 [PubMed: 24554433]
116. Piersma B, Bank RA, Boersema M. Signaling in Fibrosis: TGF-beta, WNT, and YAP/TAZ Converge. *Front Med (Lausanne).* 2015; 2:59. [PubMed: 26389119]
117. Usui T, et al. Extracellular matrix production regulation by TGF-beta in corneal endothelial cells. *Invest Ophthalmol Vis Sci.* 1998; 39:1981–1989. [PubMed: 9761276]
118. Roy O, Leclerc VB, Bourget JM, Theriault M, Proulx S. Understanding the process of corneal endothelial morphological change in vitro. *Invest Ophthalmol Vis Sci.* 2015; 56:1228–1237. DOI: 10.1167/iovs.14-16166 [PubMed: 25698769]
119. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. *Oncogene.* 2005; 24:5764–5774. DOI: 10.1038/sj.onc.1208927 [PubMed: 16123809]
120. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. *J Invest Dermatol.* 2002; 118:211–215. DOI: 10.1046/j.1523-1747.2002.01641.x [PubMed: 11841535]
121. Okumura N, et al. Involvement of ZEB1 and Snail1 in excessive production of extracellular matrix in Fuchs endothelial corneal dystrophy. *Lab Invest.* 2015
122. Okumura N, et al. Inhibition of TGF-beta signaling enables human corneal endothelial cell expansion in vitro for use in regenerative medicine. *PLoS One.* 2013; 8:e58000. [PubMed: 23451286]
123. Matthaei M, et al. Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy. *Invest Ophthalmol Vis Sci.* 2014; 55:216–225. DOI: 10.1167/iovs.13-12689 [PubMed: 24334445]
124. Matthaei M, et al. Epithelial-Mesenchymal Transition (EMT)-Related Cytokines in the Aqueous Humor of Phakic and Pseudophakic Fuchs' Dystrophy Eyes. *Invest Ophthalmol Vis Sci.* 2015; 56:2749–2754. DOI: 10.1167/iovs.15-16395 [PubMed: 26066605]
125. Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. *J Biol Chem.* 2014; 289:13461–13474. DOI: 10.1074/jbc.M113.529115 [PubMed: 24648515]
126. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. *Apoptosis.* 2004; 9:667–676. DOI: 10.1023/B:APPT.0000045801.15585.dd [PubMed: 15505410]
127. Lu J, et al. TGF-beta2 inhibits AKT activation and FGF-2-induced corneal endothelial cell proliferation. *Exp Cell Res.* 2006; 312:3631–3640. DOI: 10.1016/j.yexcr.2006.08.004 [PubMed: 16963022]

128. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. *Mol Cell*. 2003; 11:11–23. [PubMed: 12535517]
129. Ho WT, et al. Inhibition of matrix metalloproteinase activity reverses corneal endothelial-mesenchymal transition. *Am J Pathol*. 2015; 185:2158–2167. DOI: 10.1016/j.ajpath.2015.04.005 [PubMed: 26216284]
130. Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. *Genes Dev*. 2009; 23:265–277. DOI: 10.1101/gad.1760809 [PubMed: 19204114]
131. Lee JG, Kay EP. Cross-talk among Rho GTPases acting downstream of PI 3-kinase induces mesenchymal transformation of corneal endothelial cells mediated by FGF-2. *Invest Ophthalmol Vis Sci*. 2006; 47:2358–2368. DOI: 10.1167/iops.05-1490 [PubMed: 16723445]
132. Zhu YT, Chen HC, Chen SY, Tseng SC. Nuclear p120 catenin unlocks mitotic block of contact-inhibited human corneal endothelial monolayers without disrupting adherent junctions. *J Cell Sci*. 2012; 125:3636–3648. DOI: 10.1242/jcs.103267 [PubMed: 22505615]
133. Bourne WM. Biology of the corneal endothelium in health and disease. *Eye (Lond)*. 2003; 17:912–918. DOI: 10.1038/sj.eye.6700559 [PubMed: 14631396]
134. Joyce NC, Navon SE, Roy S, Zieske JD. Expression of cell cycle-associated proteins in human and rabbit corneal endothelium in situ. *Invest Ophthalmol Vis Sci*. 1996; 37:1566–1575. [PubMed: 8675399]
135. Murphy C, Alvarado J, Juster R, Maglio M. Prenatal and postnatal cellularity of the human corneal endothelium. A quantitative histologic study. *Invest Ophthalmol Vis Sci*. 1984; 25:312–322. [PubMed: 6698749]
136. Hoppenreijns VP, Pels E, Vrensen GF, Oosting J, Treffers WF. Effects of human epidermal growth factor on endothelial wound healing of human corneas. *Invest Ophthalmol Vis Sci*. 1992; 33:1946–1957. [PubMed: 1582800]
137. Matsuda M, et al. Cellular migration and morphology in corneal endothelial wound repair. *Invest Ophthalmol Vis Sci*. 1985; 26:443–449. [PubMed: 3980166]
138. Gagnon MM, Boisjoly HM, Brunette I, Charest M, Amyot M. Corneal endothelial cell density in glaucoma. *Cornea*. 1997; 16:314–318. [PubMed: 9143804]
139. Olsen T. Changes in the corneal endothelium after acute anterior uveitis as seen with the specular microscope. *Acta Ophthalmol (Copenh)*. 1980; 58:250–256. [PubMed: 7395486]
140. Liesegang TJ. The response of the corneal endothelium to intraocular surgery. *Refract Corneal Surg*. 1991; 7:81–86. [PubMed: 2043553]
141. Irvine AR Jr. The role of the endothelium in bullous keratopathy. *AMA Arch Ophthalmol*. 1956; 56:338–351. [PubMed: 13361609]
142. Schultz RO, Glasser DB, Matsuda M, Yee RW, Edelhauser HF. Response of the corneal endothelium to cataract surgery. *Arch Ophthalmol*. 1986; 104:1164–1169. [PubMed: 3741247]
143. Ventura AC, Walti R, Bohnke M. Corneal thickness and endothelial density before and after cataract surgery. *Br J Ophthalmol*. 2001; 85:18–20. [PubMed: 11133705]
144. Soumitra N, et al. Biosynthetic and functional defects in newly identified SLC4A11 mutants and absence of COL8A2 mutations in Fuchs endothelial corneal dystrophy. *J Hum Genet*. 2014; 59:444–453. DOI: 10.1038/jhg.2014.55 [PubMed: 25007886]
145. Loganathan SK, Casey JR. Corneal dystrophy-causing SLC4A11 mutants: suitability for folding-correction therapy. *Hum Mutat*. 2014; 35:1082–1091. DOI: 10.1002/humu.22601 [PubMed: 24916015]
146. Hamill CE, Schmedt T, Jurkunas U. Fuchs endothelial cornea dystrophy: a review of the genetics behind disease development. *Semin Ophthalmol*. 2013; 28:281–286. DOI: 10.3109/08820538.2013.825283 [PubMed: 24138036]
147. Bourne WM, Johnson DH, Campbell RJ. The ultrastructure of Descemet's membrane. III. Fuchs' dystrophy. *Arch Ophthalmol*. 1982; 100:1952–1955. [PubMed: 6983339]
148. Gottsch JD, et al. Inheritance of a novel COL8A2 mutation defines a distinct early-onset subtype of fuchs corneal dystrophy. *Invest Ophthalmol Vis Sci*. 2005; 46:1934–1939. DOI: 10.1167/iops.04-0937 [PubMed: 15914606]

149. Lee WR, Marshall GE, Kirkness CM. Corneal endothelial cell abnormalities in an early stage of the iridocorneal endothelial syndrome. *Br J Ophthalmol.* 1994; 78:624–631. [PubMed: 7918291]
150. Weller JM, et al. Extracellular matrix alterations in late-onset Fuchs' corneal dystrophy. *Invest Ophthalmol Vis Sci.* 2014; 55:3700–3708. DOI: 10.1167/iovs.14-14154 [PubMed: 24833739]
151. Biswas S, et al. Missense mutations in COL8A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. *Hum Mol Genet.* 2001; 10:2415–2423. [PubMed: 11689488]
152. Zhang C, et al. Immunohistochemistry and electron microscopy of early-onset fuchs corneal dystrophy in three cases with the same L450W COL8A2 mutation. *Transactions of the American Ophthalmological Society.* 2006; 104:85–97. [PubMed: 17471329]
153. Jun AS, et al. An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis. *Hum Mol Genet.* 2012; 21:384–393. DOI: 10.1093/hmg/ddr473 [PubMed: 22002996]
154. Meng H, et al. L450W and Q455K Col8a2 knock-in mouse models of Fuchs endothelial corneal dystrophy show distinct phenotypes and evidence for altered autophagy. *Invest Ophthalmol Vis Sci.* 2013; 54:1887–1897. DOI: 10.1167/iovs.12-11021 [PubMed: 23422828]
155. Bateman JF, Boot-Handford RP, Lamande SR. Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. *Nat Rev Genet.* 2009; 10:173–183. DOI: 10.1038/nrg2520 [PubMed: 19204719]
156. Klintworth GK. The molecular genetics of the corneal dystrophies--current status. *Front Biosci.* 2003; 8:d687–713. [PubMed: 12700042]
157. Chung DW, Frausto RF, Ann LB, Jang MS, Aldave AJ. Functional impact of ZEB1 mutations associated with posterior polymorphous and Fuchs' endothelial corneal dystrophies. *Invest Ophthalmol Vis Sci.* 2014; 55:6159–6166. DOI: 10.1167/iovs.14-15247 [PubMed: 25190660]
158. Baratz KH, et al. E2-2 protein and Fuchs's corneal dystrophy. *N Engl J Med.* 2010; 363:1016–1024. DOI: 10.1056/NEJMoa1007064 [PubMed: 20825314]
159. Chang PC, Sulik GI, Soong HK, Parkinson WC. Galvanotropic and galvanotoxic responses of corneal endothelial cells. *J Formos Med Assoc.* 1996; 95:623–627. [PubMed: 8870433]
160. Vilas GL, et al. Oligomerization of SLC4A11 protein and the severity of FECD and CHED2 corneal dystrophies caused by SLC4A11 mutations. *Hum Mutat.* 2012; 33:419–428. DOI: 10.1002/humu.21655 [PubMed: 22072594]
161. Riazuddin SA, et al. Mutations in LOXHD1, a recessive-deafness locus, cause dominant late-onset Fuchs corneal dystrophy. *Am J Hum Genet.* 2012; 90:533–539. DOI: 10.1016/j.ajhg.2012.01.013 [PubMed: 22341973]
162. Son HS, Villarreal G Jr, Meng H, Eberhart CG, Jun AS. On the origin of 'guttae'. *Br J Ophthalmol.* 2014; 98:1308–1310. DOI: 10.1136/bjophthalmol-2014-305069
163. Xia D, et al. The Ultrastructures and Mechanical Properties of the Descemet's Membrane in Fuchs Endothelial Corneal Dystrophy. *Sci Rep.* 2016; 6:23096. [PubMed: 26980551]
164. Thomasy, S., VKR, Ali, M., Murphy, C. *The Association for Research in Vision and Ophthalmology.* Seattle, WA: 2016.
165. Black LD, Allen PG, Morris SM, Stone PJ, Suki B. Mechanical and failure properties of extracellular matrix sheets as a function of structural protein composition. *Biophys J.* 2008; 94:1916–1929. DOI: 10.1529/biophysj.107.107144 [PubMed: 17993498]
166. Hwang ES, Brodsky B. Folding delay and structural perturbations caused by type IV collagen natural interruptions and nearby Gly missense mutations. *J Biol Chem.* 2012; 287:4368–4375. DOI: 10.1074/jbc.M111.269084 [PubMed: 22179614]
167. Hwang ES, Thiagarajan G, Parmar AS, Brodsky B. Interruptions in the collagen repeating tripeptide pattern can promote supramolecular association. *Protein Sci.* 2010; 19:1053–1064. DOI: 10.1002/pro.383 [PubMed: 20340134]
168. Muiznieks LD, Keeley FW. Molecular assembly and mechanical properties of the extracellular matrix: A fibrous protein perspective. *Biochim Biophys Acta.* 2013; 1832:866–875. DOI: 10.1016/j.bbdis.2012.11.022 [PubMed: 23220448]
169. Mehta, JS., et al. ARVO 2016 Annual Meeting;

170. Tocce EJ, et al. The ability of corneal epithelial cells to recognize high aspect ratio nanostructures. *Biomaterials*. 2010; 31:4064–4072. DOI: 10.1016/j.biomaterials.2010.01.101 [PubMed: 20153044]
171. Bergmanson JP, Sheldon TM, Goosey JD. Fuchs' endothelial dystrophy: a fresh look at an aging disease. *Ophthalmic Physiol Opt*. 1999; 19:210–222. [PubMed: 10627840]
172. Heise RL, Stober V, Chelvaraju C, Hollingsworth JW, Garantziotis S. Mechanical stretch induces epithelial-mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. *J Biol Chem*. 2011; 286:17435–17444. DOI: 10.1074/jbc.M110.137273 [PubMed: 21398522]
173. Thomasy SM, et al. In Vivo Imaging of Corneal Endothelial Dystrophy in Boston Terriers: A Spontaneous, Canine Model for Fuchs' Endothelial Corneal Dystrophy. *Invest Ophthalmol Vis Sci*. 2016; 57:OCT495–OCT503. DOI: 10.1167/iops.15-18885
174. Bozkurt B, Irkeç M, Mocan MC. In vivo confocal microscopic findings in posterior polymorphous corneal dystrophy. *Cornea*. 2013; 32:1237–1242. DOI: 10.1097/ICO.0b013e31828e324d [PubMed: 23635854]
175. Henriquez AS, et al. Morphologic characteristics of posterior polymorphous dystrophy. A study of nine corneas and review of the literature. *Surv Ophthalmol*. 1984; 29:139–147. [PubMed: 6334374]
176. Mahmood MA, Teichmann KD. Corneal amyloidosis associated with congenital hereditary endothelial dystrophy. *Cornea*. 2000; 19:570–573. [PubMed: 10928782]
177. Vemuganti GK, Sridhar MS, Edward DP, Singh S. Subepithelial amyloid deposits in congenital hereditary endothelial dystrophy: a histopathologic study of five cases. *Cornea*. 2002; 21:524–529. [PubMed: 12072731]
178. Pandrowala H, Bansal A, Vemuganti GK, Rao GN. Frequency, distribution, and outcome of keratoplasty for corneal dystrophies at a tertiary eye care center in South India. *Cornea*. 2004; 23:541–546. [PubMed: 15256989]
179. Al-Shehah A, Al-Rajhi A, Alkatan H. Amyloid corneal deposition in corneal buttons of congenital hereditary endothelial dystrophy (CHED) - A clinical and histopathological case series. *Saudi J Ophthalmol*. 2010; 24:111–118. DOI: 10.1016/j.sjopt.2010.06.001 [PubMed: 23960887]
180. Schmid E, et al. A new, X-linked endothelial corneal dystrophy. *American journal of ophthalmology*. 2006; 141:478–487. DOI: 10.1016/j.ajo.2005.10.020 [PubMed: 16490493]
181. Sacchetti M, et al. Diagnosis and Management of Iridocorneal Endothelial Syndrome. *Biomed Res Int*. 2015; 2015:763093. [PubMed: 26451377]
182. Levy SG, et al. Descemet's membrane in the iridocorneal-endothelial syndrome: morphology and composition. *Exp Eye Res*. 1995; 61:323–333. [PubMed: 7556496]
183. Zhang J, Patel DV. The pathophysiology of Fuchs' endothelial dystrophy--a review of molecular and cellular insights. *Exp Eye Res*. 2015; 130:97–105. DOI: 10.1016/j.exer.2014.10.023 [PubMed: 25446318]
184. Gjorevski N, Boghaert E, Nelson CM. Regulation of Epithelial-Mesenchymal Transition by Transmission of Mechanical Stress through Epithelial Tissues. *Cancer Microenviron*. 2012; 5:29–38. DOI: 10.1007/s12307-011-0076-5 [PubMed: 21748438]
185. Zhang YH, Zhao CQ, Jiang LS, Dai LY. Substrate stiffness regulates apoptosis and the mRNA expression of extracellular matrix regulatory genes in the rat annular cells. *Matrix Biol*. 2011; 30:135–144. DOI: 10.1016/j.matbio.2010.10.008 [PubMed: 21055467]
186. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. *Dis Model Mech*. 2011; 4:165–178. DOI: 10.1242/dmm.004077 [PubMed: 21324931]
187. Kothapalli D, et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. *Cell Rep*. 2012; 2:1259–1271. DOI: 10.1016/j.celrep.2012.09.018 [PubMed: 23103162]


188. Tseng SC, Savion N, Gospodarowicz D, Stern R. Characterization of collagens synthesized by cultured bovine corneal endothelial cells. *J Biol Chem.* 1981; 256:3361–3365. [PubMed: 7204405]
189. Perlman M, Baum JL. Synthesis of a collagenous basal membrane by rabbit corneal endothelial cells in vitro. *Arch Ophthalmol.* 1974; 92:238–239. [PubMed: 4854572]
190. Kay EP, Gu X, Ninomiya Y, Smith RE. Corneal endothelial modulation: a factor released by leukocytes induces basic fibroblast growth factor that modulates cell shape and collagen. *Invest Ophthalmol Vis Sci.* 1993; 34:663–672. [PubMed: 8449685]
191. Lee JG, Ko MK, Kay EP. Endothelial mesenchymal transformation mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. *Exp Eye Res.* 2012; 95:35–39. DOI: 10.1016/j.exer.2011.08.003 [PubMed: 21855543]
192. Raphael B, Lange T, Wood TO, McLaughlin BJ. Growth of human corneal endothelium on altered Descemet's membrane. *Cornea.* 1992; 11:242–249. [PubMed: 1587133]
193. Choi JS, et al. In vitro evaluation of the interactions between human corneal endothelial cells and extracellular matrix proteins. *Biomed Mater.* 2013; 8:014108. [PubMed: 23353814]
194. Palchesko, RN., Funderburgh, JL., Feinberg, AW. Biomedical Engineering Society.
195. Castaldo C, et al. Cardiac fibroblast-derived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart. *Biomed Res Int.* 2013; 2013:352370. [PubMed: 23738325]
196. Zavala J, Lopez Jaime GR, Rodriguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: developmental strategies for regeneration. *Eye (Lond).* 2013; 27:579–588. DOI: 10.1038/eye.2013.15 [PubMed: 23470788]
197. Mimura T, Yamagami S, Amano S. Corneal endothelial regeneration and tissue engineering. *Progress in retinal and eye research.* 2013; 35:1–17. DOI: 10.1016/j.preteyeres.2013.01.003 [PubMed: 23353595]
198. Senoo T, Obara Y, Joyce NC. EDTA: a promoter of proliferation in human corneal endothelium. *Invest Ophthalmol Vis Sci.* 2000; 41:2930–2935. [PubMed: 10967047]
199. Chen KH, Azar D, Joyce NC. Transplantation of adult human corneal endothelium ex vivo: a morphologic study. *Cornea.* 2001; 20:731–737. [PubMed: 11588426]
200. Whikehart DR, Parikh CH, Vaughn AV, Mishler K, Edelhauser HF. Evidence suggesting the existence of stem cells for the human corneal endothelium. *Mol Vis.* 2005; 11:816–824. [PubMed: 16205623]
201. Mimura T, Yokoo S, Araie M, Amano S, Yamagami S. Treatment of rabbit bullous keratopathy with precursors derived from cultured human corneal endothelium. *Invest Ophthalmol Vis Sci.* 2005; 46:3637–3644. DOI: 10.1167/iovs.05-0462 [PubMed: 16186344]
202. Bayyoud T, et al. Decellularized bovine corneal posterior lamellae as carrier matrix for cultivated human corneal endothelial cells. *Curr Eye Res.* 2012; 37:179–186. DOI: 10.3109/02713683.2011.644382 [PubMed: 22335804]
203. Ishino Y, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. *Invest Ophthalmol Vis Sci.* 2004; 45:800–806. [PubMed: 14985293]
204. Yoeruek E, et al. Human anterior lens capsule as carrier matrix for cultivated human corneal endothelial cells. *Cornea.* 2009; 28:416–420. DOI: 10.1097/ICO.0b013e31818c2c36 [PubMed: 19411960]
205. Gruschwitz R, et al. Alignment and cell-matrix interactions of human corneal endothelial cells on nanostructured collagen type I matrices. *Invest Ophthalmol Vis Sci.* 2010; 51:6303–6310. DOI: 10.1167/iovs.10-5368 [PubMed: 20631237]
206. Mimura T, et al. Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model. *Invest Ophthalmol Vis Sci.* 2004; 45:2992–2997. DOI: 10.1167/iovs.03-1174 [PubMed: 15326112]
207. Madden PW, et al. Human corneal endothelial cell growth on a silk fibroin membrane. *Biomaterials.* 2011; 32:4076–4084. DOI: 10.1016/j.biomaterials.2010.12.034 [PubMed: 21427010]

208. Gao X, Liu W, Han B, Wei X, Yang C. Preparation and properties of a chitosan-based carrier of corneal endothelial cells. *J Mater Sci Mater Med*. 2008; 19:3611–3619. DOI: 10.1007/s10856-008-3508-0 [PubMed: 18642061]
209. Desgranges P, Tardieu M, Loisanche D, Barritault D. Extracellular matrix covered biomaterials for human endothelial cell growth. *Int J Artif Organs*. 1992; 15:722–726. [PubMed: 1493948]
210. Underwood PA, Bennett FA. The effect of extracellular matrix molecules on the in vitro behavior of bovine endothelial cells. *Exp Cell Res*. 1993; 205:311–319. DOI: 10.1006/excr.1993.1091 [PubMed: 7683271]
211. Blake DA, Yu H, Young DL, Caldwell DR. Matrix stimulates the proliferation of human corneal endothelial cells in culture. *Invest Ophthalmol Vis Sci*. 1997; 38:1119–1129. [PubMed: 9152231]
212. Wang TJ, Wang IJ, Chen S, Chen YH, Young TH. The phenotypic response of bovine corneal endothelial cells on chitosan/polycaprolactone blends. *Colloids Surf B Biointerfaces*. 2012; 90:236–243. DOI: 10.1016/j.colsurfb.2011.10.043 [PubMed: 22078926]
213. Chen J, et al. Electrospun nanofibrous SF/P(LLA-CL) membrane: a potential substratum for endothelial keratoplasty. *Int J Nanomedicine*. 2015; 10:3337–3350. DOI: 10.2147/IJN.S77706 [PubMed: 26005345]
214. Hsiue GH, Lai JY, Chen KH, Hsu WM. A novel strategy for corneal endothelial reconstruction with a bioengineered cell sheet. *Transplantation*. 2006; 81:473–476. DOI: 10.1097/01.tp.0000194864.13539.2c [PubMed: 16477237]
215. Gotze T, et al. Cultivation of an immortalized human corneal endothelial cell population and two distinct clonal subpopulations on thermo-responsive carriers. *Graefes Arch Clin Exp Ophthalmol*. 2008; 246:1575–1583. DOI: 10.1007/s00417-008-0904-6 [PubMed: 18696098]
216. Hadlock T, Singh S, Vacanti JP, McLaughlin BJ. Ocular cell monolayers cultured on biodegradable substrates. *Tissue Eng*. 1999; 5:187–196. [PubMed: 10434067]

Research Highlights

- Descemet's membrane presents biophysical cues to endothelial cells
- Mechanotransduction influences cell behavior such as matrix production
- In dynamic reciprocity, biophysical cues and matrix production modulate each other
- Understanding these relationships helps develop models for corneal dystrophies

1(a)








Figure 1. The basements membranes of the canine cornea

(a) Scanning electron micrograph of the canine corneal epithelial basement membrane. The basement membrane has an intricate surface topography consisting of a meshwork of fibers and pores. (Reprinted with permission from Bentley et al., 2001. ©Association for Research in Vision and Ophthalmology) (b) Scanning electron micrograph of Descemet's membrane of the canine cornea. The complex topography of intertwined fibers and pores of varying sizes is similar to the topography found in the epithelial basement membrane. (Reprinted with permission from Abrams et al., 2002.)


(a)




(b)





(c)




(d)






(g)



(h)



(i)




Figure 2. The assembly of Collagen VIII, an extracellular matrix protein critical in the assembly of Descemet's membrane

It comprises two types of polypeptide chains, $\alpha 1(\text{VIII})$ and $\alpha 2(\text{VIII})$ consisting of (a) two globular domains, the larger on the C-terminal side, connected by a rod-like triple-helical domain. (b) These polypeptides can form homotrimers. (c) Four of these homotrimers may associate through their C-terminal domains to form tetrahedral assemblies. These tetrahedra may assemble further via (d) N- to N-terminal interactions or (e) N- to C-terminal interactions. (f) Extended networks of Collagen VIII assemblies may form a hexagonal network that (g) stacks vertically, shown here based on N- to N-terminal interactions. This theorized assembly pattern of Collagen VIII corresponds to the ultrastructure of Collagen VIII, imaged through transmission electron microscopy in Descemet's membrane. (h) In the en face section, Collagen VIII appears as a hexagonal network, whereas (i) in the transverse section it appears as parallel bands. The imaged ultrastructure supports the theorized assembly of Collagen VIII. (h) reprinted with permission from Sawada 1982. (i) reprinted

with permission from Klintworth, 2009, licensed under the Creative Commons Attribution 2.0 Generic License)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Dynamic Reciprocity

Cells synthesize ECM proteins and deposit them into the extracellular space. The proteins assemble the matrix, presenting a rich set of topography and modulus cues to the cells. Integrins, syndecans, and other receptors mechanotransduce biophysical cues into the cells. Signaling molecules and the cytoskeleton convey these signals to the nucleus, where they influence cell behavior in many ways, including through changes in the expression of ECM genes and proteins.




Figure 4. Signaling pathways linked to mechanotransduction

(a) Mechanical regulation of the Hippo pathway. Hippo is regulated by multiple signals generated by the physical (matrix stiffness) and biochemical (e.g. LPA, thrombin) environment. Importantly, many of these signals are modulated by tension in the actinomyosin cytoskeleton. Modulation of cytoskeletal mechanics through G-protein coupled receptors and matrix biophysics can likewise inhibit YAP/TAZ directly at the nuclear translocation stage or through activation of Hippo components. Note: This schematic is simplified to clarify the major components in the mechanical regulation of YAP/TAZ signaling. (b) Crosstalk between YAP/TAZ and TGF- β , and between YAP/TAZ and Wnt. TGF- β superfamily signaling is initiated by the binding of an extracellular ligand (e.g. TGF- β and BMP), which leads to the phosphorylation of SMADs and the formation of a complex with a Co-SMAD and 14-3-3s. After translocation to the nucleus, these complexes initiate the TGF- β /BMP transcriptional program. The SMAD complex also interacts with YAP/TAZ to initiate different transcriptional programs in the nucleus. Canonical Wnt is initiated by the binding of a Wnt ligand to the Fzd/LRP receptor complex. This induces the inhibitory behavior of Dvl on the Axin/APC/GSK3b complex, freeing β -catenin to translocate to the nucleus and initiate the Wnt transcriptional program. YAP/TAZ can inhibit Wnt signaling through inhibition of Dvl in the cytoplasm (TAZ) or in the nucleus (YAP) or cytoplasmic sequestration of β -catenin (YAP). Alternatively, YAP can encourage the transcriptional activity of β -catenin. Note: This schematic is simplified to clarify the intersections of YAP/TAZ and Wnt signaling. (Adapted with permission from Morgan, 2013)

Table 1

A comparison of measurements of the stiffness of Descemet's membrane in various species using different several analytical methods. In the mechanical interferometry imaging data set, the "short term" value refers to an instantaneous measurement whereas the "long term" values refers to a time dependent measurement including non-linear effects in response to constant stress over a 200 sec interval. Atomic Force Microscopy measurements were instantaneous. Measured values are highly dependent on analytical methods, making it necessary to consider the strengths and limitations of each method during experimental design and data interpretation.

Species	Modulus	Measurement technique
Rat	$2.81 \pm 0.51 \text{ MPa}^{50}$	Tensile testing
Cow	$6.14 \pm 0.41 \text{ MPa}^{50}$	Tensile testing
Pig	$4.29 \pm 0.35 \text{ MPa}^{50}$	Tensile testing
Human	$2.57 \pm 0.37 \text{ MPa}^{50}$ $50 \pm 17.8 \text{ kPa}^{45}$ $339.2 \pm 22.2 \text{ kPa}$ (short term) and $20.2 \pm 0.71 \text{ kPa}$ (long term) ⁴³ $1.8 \pm 0.8 \text{ MPa}$ (hydrated) and $4.8 \pm 1.2 \text{ GPa}$ (dehydrated) ¹⁶³	Tensile testing Atomic Force Microscopy Mechanical Interferometry Imaging
Rabbit	$11.7 \pm 7.4 \text{ kPa}^{47}$	Atomic Force Microscopy

Table 2

Elastic moduli of corneal layers as measured by atomic force microscopy (AFM) in humans and rabbits.

Corneal layer	Elastic Modulus	
	Humans	Rabbits
Anterior Basement Membrane	7.5 ± 4.2 kPa ⁴⁵	4.5 ± 1.2 kPa ⁴⁷
Bowman's Layer	109.8 ± 13.2 kPa ⁴⁶	Absent
Stroma	33.1 ± 6.1 kPa ⁴⁶	1.1 ± 0.6 kPa (anterior face) 0.38 ± 0.22 kPa (posterior face) ⁴⁷
Descemet's membrane	50 ± 17.8 kPa ⁴⁵ 1.8 ± 0.8 MPa (hydrated) and 4.8 ± 1.2 GPa (dehydrated) ¹⁶³	11.7 ± 7.4 kPa ⁴⁷
Endothelium		4.1 ± 1.7 kPa ⁴⁷